Cerapedics, Inc.
Cerapedics is dedicated to enhancing the science of bone repair by staying at the leading edge of osteobiologic science and product development. Our lead technology platform (i-FACTOR Peptide Enhanced Bone Graft) is the only biologic bone graft that uses a unique small peptide attachment factor (P-15) bound to anorganic bone mineral (ABM). This novel (ABM/P-15) combination acts as an attachment factor for osteogenic cells.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical Equipment
- Market Focus:
- Globally (various continents)
- Year Founded:
- 2001
- Employees:
- 101-1000
History
The first P-15 enhanced bone graft substitute was developed for use in the oral cavity by CeraMed Dental – the precursor to Cerapedics – under the leadership of Andrew J. Tofe, PhD. The product received PMA approval in 1999 based on the results of two prospective multi-center investigations. It remains the only dental bone graft substitute with FDA approved claims of superiority over demineralized bone matrix (DBM) allograft and alloplasts. Since approval, ABM/P-15 has been used in an estimated 500,000 procedures.
From these roots, Cerapedics has reformulated the (ABM/P-15) product and branded it i-FACTOR Peptide Enhanced Bone Graft to capture the unique “attachment factor” mechanism of action. Cerapedics is now actively involved in introducing the i-FACTOR Bone Graft technology platform into the rapidly expanding market for osteobiologic products.
Team
The Cerapedics team is dedicated to enhancing the science of bone repair by staying at the leading edge of osteobiologic science and product development.
To find out more about the Cerapedics Board and Leadership Team, please see below.